ZGNX

Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans

[GlobeNewswire] – SAN DIEGO — Zogenix, Inc. , a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it has made … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Acura Pharma rises on FDA OxyContin decision

moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results

[at noodls] – Conference Call Scheduled for March 15, 2013 at 8:30 am ET SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Zogenix Provides Update on Zohydro(TM) ER Regulatory Review

[at noodls] – SAN DIEGO, Feb. 26, 2013 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales

[at noodls] – SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

[at noodls] – Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) — Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to view […]

Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain

[at noodls] – Zogenix to Host Conference Call on Dec. 7, 2012 at 6:30 p.m. ET SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here to […]

Trading of Zogenix Common Stock Halted

[at noodls] – FDA Advisory Committee Reviewing Zohydroâ„¢ ER New Drug Application Zogenix to Host Conference Call at 6:30 pm ET Today SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboardSee who Zogenix is hiring next, click here […]

Zogenix Appoints New Chief Commercial Officer

[at noodls] – SAN DIEGO, Nov. 26, 2012 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, … moreView todays social media effects on ZGNXView the latest stocks trending across Twitter. Click to view dashboard […]